Asia Pacific Radiology Information Systems (RIS) Market Growth and Forecast by 2027

The Asia-Pacific immunochemistry market is expected to reach US$ 795.05 Mn in 2027 from US$ 436.79 Mn in 2019. The market is estimated to grow with a CAGR of 7.8% from 2019-2027.

The growth of the market is driven by the factors such as, rising incidences of chronic and infectious diseases and increasing geriatric population.However, the market is likely to slower down its growth due to the limitations associated with immunohistochemistry.

The countries in the region are creating significant opportunities for the key market players to expand their business. It is likely to be a major factor contributing to the Asia Pacific Radiology Information Systems (RIS) market growth during the coming years. With rising costs of production against their practices, the healthcare companies are striving to produce sufficient revenue to entertain their investors. The markets in some growing economies are expected to be an essential part of offering more reliable and profitable growth opportunities for the major players to expand their industry and geographic scope.

Also, the rising advancements in the biotechnology have increased the demand for diagnostics in the healthcare market, encouraging the introduction of a more significant number of immunoassay systems and facilitating the shift toward personalized medicine. There are new opportunities in infectious disease testing, molecular oncology, and pharmacogenomics in emerging countries. Hence, healthcare companies can target patients or consumers in a developing nation.

The increasing investments in R&D activities have paved the way for the growth of the industry in the future years. Many scientists, in partnership with other scientists in China, offer various products for bioreactors. For instance, in April 2018, BIO attended meetings with members of the Chinese biotech community and government leaders. The conference aims the commitment on behalf of the western biotechnology industry for encouraging China to strengthen its support for biotech innovation. They aim to and take steps to enhance more significant investment and collaboration with companies in China. Thus, the rising number of infectious disease incidences and advancements are likely to boost the market and are anticipated to provide significant growth opportunities to the players operating in the market during the forecast period.

The China is expected to lead the market in the Asia-Pacific region owing to the rapidly increasing incidence of chronic diseases like cancer in the country and the growing demand for diagnostics. Furthermore, the increasing prevalence of diabetes is also likely to grow the market of immunohistochemistry. Therefore, considering the above-mentioned factors, the growth of the market in the country is expected to contribute the largest share in the Asia-Pacific region during the forecast period.

China Immunohistochemistry Market Revenue and Forecasts to 2027 (US$ Mn)

ASIA-PACIFICIMMUNOHISTOCHEMISTRY – MARKET SEGMENTATION

By Product

• Antibodies
• Primary Antibodies
• Secondary Antibodies
• Equipment
• Slide Staining Systems
• Tissue Microarray Systems
• Slide Scanners
• Other Equipment
• Reagents
• Histological Stains
• Blocking and Fixation Reagents
• Chromogenic Substrates
• Stabilizers
• Solvents
• Proteolytic Enzymes
• Kits

By Application

• Diagnostics
• Cancer
• Infectious Diseases
• Autoimmune Diseases
• Diabetes Mellitus
• Nephrological Diseases
• Drug Testing

By End User

• Hospitals and Diagnostic Laboratories
• Research Institutes
• Others

By Geography

• North America

  • US
  • Canada
  • Mexico

Company Profiles

• PerkinElmer, Inc.
• Abcam Plc
• Agilent Technologies,
• Bio SB
• Bio-Rad Laboratories, Inc.
• Cell Signalling Technology, Inc.
• F. Hoffmann-La Roche Ltd.
• Danaher
• Merck KGaA
• Thermo Fisher Scientific, Inc.

Asia Pacific Radiology Information Systems (RIS) Report Scope